1. Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX).
- Author
-
Uckun FM, Orhan C, Powell J, Sahin E, Ozercan IH, Volk M, and Sahin K
- Subjects
- Animals, Female, Male, Rats, Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents therapeutic use, Antioxidants chemistry, Antioxidants pharmacology, Antioxidants therapeutic use, Dose-Response Relationship, Drug, Drug Combinations, Drug Compounding, Lipopolysaccharides toxicity, Mice, Inbred BALB C, Oxidative Stress drug effects, Oxidative Stress physiology, Rats, Sprague-Dawley, Rats, Wistar, Superoxide Dismutase metabolism, Mice, Ascorbic Acid chemistry, Ascorbic Acid pharmacology, Ascorbic Acid therapeutic use, Magnesium Sulfate chemistry, Magnesium Sulfate pharmacology, Magnesium Sulfate therapeutic use, Niacinamide chemistry, Niacinamide pharmacology, Niacinamide therapeutic use, Pantothenic Acid chemistry, Pantothenic Acid pharmacology, Pantothenic Acid therapeutic use, Pyridoxine chemistry, Pyridoxine pharmacology, Pyridoxine therapeutic use, Riboflavin chemistry, Riboflavin pharmacology, Riboflavin therapeutic use, Sepsis drug therapy, Sepsis metabolism, Sepsis pathology, Thiamine chemistry, Thiamine pharmacology, Thiamine therapeutic use
- Abstract
Here, we demonstrate that the two distinct formulations of our anti-sepsis drug candidate Rejuveinix (RJX), have a very favorable safety profile in Wistar Albino rats at dose levels comparable to the projected clinical dose levels. 14-day treatment with RJX-P (RJX PPP.18.1051) or RJX-B (RJX-B200702-CLN) similarly elevated the day 15 tissue levels of the antioxidant enzyme superoxide dismutase (SOD) as well as ascorbic acid in both the lungs and liver in a dose-dependent fashion. The activity of SOD and ascorbic acid levels were significantly higher in tissues of RJX-P or RJX-B treated rats than vehicle-treated control rats (p < 0.0001). There was no statistically significant difference between tissue SOD activity or ascorbic acid levels of rats treated with RJX-P vs. rats treated with RJX-B (p > 0.05). The observed elevations of the SOD and ascorbic acid levels were transient and were no longer detectable on day 28 following a 14-day recovery period. These results demonstrate that RJX-P and RJX-B are bioequivalent relative to their pharmacodynamic effects on tissue SOD and ascorbic acid levels. Furthermore, both formulations showed profound protective activity in a mouse model of sepsis. In agreement with the PD evaluations in rats and their proposed mechanism of action, both RJX-P and RJX-B exhibited near-identical potent and dose-dependent anti-oxidant and anti-inflammatory activity in the LPS-GalN model of ARDS and multi-organ failure in mice., (Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF